Hengdian Group Capital

Hengdian Group Capital is a Chinese private investment firm with a diversified portfolio spanning multiple sectors, including biotechnology, pharmaceuticals, electronics, and entertainment. The firm is a wholly-owned subsidiary of Hengdian Group, a conglomerate founded in 1975 in Zhejiang, China. Hengdian Group Capital focuses on investments that align with the strategic interests of its parent company, aiming to enhance value across its diverse business operations. The firm's investment strategy encompasses a wide range of asset classes, including private equity, venture capital, real estate, infrastructure, fixed income, hedge funds, commodities, collectibles, crypto, distressed and special situations, and ESG and impact investing. Hengdian Group Capital engages in investments at various stages, from seed and early-stage funding to growth, late-stage, pre-IPO, buyouts, turnarounds, and distressed situations. This comprehensive approach allows the firm to support a diverse array of companies and projects. Geographically, Hengdian Group Capital's investments span across multiple countries, including China, the United States, Japan, Germany, the Netherlands, Italy, Singapore, South Korea, India, Brazil, Australia, the United Kingdom, France, Canada, Russia, Mexico, South Africa, Argentina, Saudi Arabia, and the United Arab Emirates. The firm's industry focus is equally broad, encompassing technology, healthcare, entertainment, financial services, manufacturing, energy, consumer goods, automotive, pharmaceuticals, chemicals, media, telecommunications, retail, real estate, and logistics. This extensive reach reflects Hengdian Group Capital's commitment to fostering growth and innovation across a wide spectrum of industries and regions.

Alignment with Hengdian Group's strategic interests, Strong growth potential, Synergistic value to the Group's existing portfolio